QGEN
NYSE · Life Sciences Tools & Services
Qiagen N.V.
$42.30
+0.57 (+1.37%)
Financial Highlights (FY 2026)
Revenue
1.97B
Net Income
400.79M
Gross Margin
63.7%
Profit Margin
20.3%
Rev Growth
-0.8%
D/E Ratio
0.44
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 63.7% | 63.7% | 30.4% | 30.4% |
| Operating Margin | 22.2% | 20.0% | 6.7% | 6.5% |
| Profit Margin | 20.3% | 19.3% | 4.1% | 4.8% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 1.97B | 1.99B | 2.80B | 2.83B |
| Gross Profit | 1.26B | 1.27B | 851.01M | 860.99M |
| Operating Income | 437.08M | 396.59M | 188.75M | 184.86M |
| Net Income | 400.79M | 363.65M | 113.25M | 136.27M |
| Gross Margin | 63.7% | 63.7% | 30.4% | 30.4% |
| Operating Margin | 22.2% | 20.0% | 6.7% | 6.5% |
| Profit Margin | 20.3% | 19.3% | 4.1% | 4.8% |
| Rev Growth | -0.8% | -0.8% | +10.7% | +5.3% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 1.33B | 1.33B | 2.25B | 2.65B |
| Total Equity | 3.03B | 3.03B | 7.69B | 7.73B |
| D/E Ratio | 0.44 | 0.44 | 0.29 | 0.34 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | 444.63M | 425.85M | 241.59M | 268.48M |
| Free Cash Flow | — | — | 174.05M | 184.00M |